330
Participants
Start Date
June 4, 2018
Primary Completion Date
June 4, 2026
Study Completion Date
June 4, 2026
BIIB111
Administered as specified in the treatment arm.
BIIB112
Administered as specified in the treatment arm.
Rigshospitalet-Glostrup, Oejenafdelingen, Glostrup Municipality
Columbia University Medical Center, New York
Vitreo Retinal Associates PA - The Millennium Center, Gainesville
University of Miami, Miami
CHU Montpellier - Saint Eloi, Montpellier
Universitäts-Augenklinik Bonn, Bonn
Universitats Klinikum Tubingen - Institute for Ophthalmic Research, Tübingen
Centre Hospitalier National d Ophtalmologie (CHNO) des Quinze-Vingts, Paris
OHSU - Casey Eye Institute, Portland
UCLA - Jules Stein Eye Institute, Los Angeles
Johns Hopkins Hospital, Baltimore
MEEI Massachusets Eye and Ear Infirmary, Boston
Cincinnati Eye Institute - Blue Ash, Cincinnati
Retina Foundation of the Southwest, Dallas
University of Wisconsin School of Medicine, Madison
Instituto Genetica Ocular, São Paulo
The Northern Alberta Clinical Trials and Research Centre, Edmonton
The University of British Columbia - Eye Care Centre, Vancouver
McGill University Health Centre, Montreal
Helsinki University Central Hospital (HUCH), Helsinki
Radboudumc, Nijmegen
Moorfields Eye Hospital, London
Manchester Royal Eye Hopsital, Manchester
John Radcliffe Hospital, Oxford
Southampton General Hospital, Southampton
NightstaRx Ltd, a Biogen Company
OTHER